{
    "nctId": "NCT00727948",
    "briefTitle": "The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy",
    "officialTitle": "The Impact of the Anti-Platelet Agent Aspirin on Angiogenesis Proteins in Women With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Angiogenesis",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 11,
    "primaryOutcomeMeasure": "Changes in pro-angiogenic and anti-angiogenic protein levels.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically proven breast cancer\n* Pre or post-menopausal\n* Age \\>18\n* Completed adjuvant non-hormonal therapy \\>30 days prior to initiation of study (surgery and/or chemotherapy and/or radiation therapy)\n* Platelet count and hemoglobin within normal ranges for local lab within 30 days of initiation of study therapy\n* Receiving tamoxifen therapy for at least 90 days prior to initiation of study therapy, and is expected to continue that therapy for the duration of the study (75 days)\n\nExclusion Criteria:\n\n* Chemotherapy, radiation therapy or surgery within 30 days of study therapy\n* Current use of aspirin, anti-platelet or anti-coagulation agents on a continuous basis\n* Prior history of gastrointestinal or central nervous system bleeding, or documented or self-reported blood in stools or bright red blood per rectum",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}